DENVER, Oct. 2 /PRNewswire/ -- Matthew B. Wiener, PharmD, Chief Executive Officer of Pharmatech, Inc., was recently awarded the Outstanding Cancer Leadership Award from the Colorado Cancer Coalition. The award is being presented to Dr. Wiener for his development of the Just-In-Time (JIT) enrollment methodology for cancer clinical trials. Dr. Wiener will accept his award on the evening of October 6th, at the St. Mary's Cancer Center, which will take place during the Colorado Cancer Summit, October 6th and 7th, in Grand Junction, Colorado.
The Just-In-Time methodology has been utilized at various Pharmatech research network sites within the state of Colorado as a means to increase enrollment in cancer clinical trials for rare disease indications. The JIT strategy puts the patient first in regards to enrolling into a clinical trial, as cancer patients are treated in a more efficient manner and drug sponsors see their trials completed in a shorter time frame. Matthew Wiener states that, "It is a high honor to receive such a distinguished award from the Colorado Cancer Coalition. Their recognition of our JIT program gives the program clout within the pharmaceutical and bioscience industries."
Matthew Wiener has dedicated the past 20 years to clinical research and his JIT program has been featured in abstracts and poster presentations at annual meetings, including the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).
About Pharmatech, Inc.:
Pharmatech, headquartered in Denver, Colorado, is a Research Management
Organization (RMO) dedicated to the highest quality of clinical research.
Pharmatech provides services of a Site Management Organization (SMO) and a
Contract Research Organization (CRO) with a focus in oncology clinical
trials. Through an organized research network, the Company focuses on the
development and utilization of therapeutic products among sponsors,
investigators, and patients. Fo
|SOURCE Pharmatech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved